You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR3

Showing 1 - 25 of 321
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)

Recruiting
  • Urinary Bladder Neoplasms
  • +2 more
  • New York, New York
  • +2 more
Jan 31, 2023

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Bladder Cancer Trial in Indianapolis, Baltimore, Rockledge (Dovitinib)

Terminated
Has Results
  • Bladder Cancer
  • Indianapolis, Indiana
  • +2 more
Jul 7, 2022

Bladder Cancer Trial in Vandœuvre-lès-Nancy (Urine collection (150ml), Blood sample (20 ml))

Recruiting
  • Bladder Cancer
  • Urine collection (150ml)
  • Blood sample (20 ml)
  • Vandœuvre-lès-Nancy, France
    Institut de Cancérologie de Lorraine
Mar 23, 2022

Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)

Recruiting
  • Bladder Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 22, 2022

Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy Trial in Arlington Heights (Panzyga IVIG,

Not yet recruiting
  • Small Fiber Neuropathy
  • +3 more
  • Panzyga IVIG
  • Placebo
  • Arlington Heights, Illinois
    Northwest Community Healthcare
Aug 22, 2022

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)

Recruiting
  • Gastrointestinal Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Dec 7, 2022

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Recruiting
  • Bladder Cancer
  • +12 more
  • Raleigh, North Carolina
    xCures Virtual Site
Sep 20, 2021

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Palo Alto, California
  • +9 more
Aug 2, 2022

Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy Trial in Boston (Intravenous immunoglobulin, 0.9% Sodium Chloride)

Active, not recruiting
  • Small Fiber Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Intravenous immunoglobulin
  • 0.9% Sodium Chloride
  • Boston, Massachusetts
    Beth Israel Deaconness Medical Center
Apr 16, 2021

Characterization of Anti-FGFR3 Antibodies

Recruiting
  • Sensory Peripheral Neuropathy
  • Neurological assessment and Blood sample
  • Bordeaux, France
  • +16 more
May 17, 2021

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)

Active, not recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)

Recruiting
  • Achondroplasia
  • Parkville, Victoria, Australia
  • +3 more
Apr 5, 2022

Solid Tumor Trial in Worldwide (Debio 1347)

Terminated
  • Solid Tumor
  • Debio 1347
  • Scottsdale, Arizona
  • +104 more
Mar 30, 2022

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022

Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Phoenix, Arizona
  • +36 more
Jan 27, 2023